CD40 and melanoma: First, we found that subcutaneous tumors from TC-1 (lung adenocarcinoma) and B16 (melanoma) cancer cells were responsive to combined anti-CD40/anti-PD-1 immunotherapy in WT mice but resisted treatment in Keap1flox/flox VavCre mice (figure 7H,I).